Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291187 · ClinicalTrials.gov registry record · Phase 3
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT00291187: Completed Phase 3 study, sponsored by Vanda Pharmaceuticals.
NCT00291187 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 411 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00291187, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Primary Outcome
The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
Interventions
- DRUG Placebo
- DRUG 20 mg VEC-162
- DRUG 50 mg VEC-162
- DRUG 100 mg VEC-162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00291187 record still lists
NCT00291187 is an interventional study that assigns participants to a tested intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00291187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00291187 about?
NCT00291187 is a clinical study titled "VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia". The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
What is the current status of trial NCT00291187?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2006-02. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00291187?
The interventions under investigation include: Placebo (DRUG), 20 mg VEC-162 (DRUG), 50 mg VEC-162 (DRUG), 100 mg VEC-162 (DRUG).
Who is sponsoring clinical trial NCT00291187?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00291187's enrollment target sits among peer trials
411 909th of 2000 higher than 1,092 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia